Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Chairman and CEO, Ron Bentsur, will be presenting at the event on September 9, 2024, at 12:00 PM ET.
Nuvectis focuses on developing innovative treatments for serious conditions with unmet medical needs in oncology. This presentation at a prominent investment conference provides an opportunity for the company to showcase its progress and potential to investors and industry professionals. Interested parties can access the presentation through a provided link, offering insight into Nuvectis' current projects and future prospects in the oncology field.
Nuvectis Pharma (NASDAQ: NVCT), un'azienda biofarmaceutica in fase clinica specializzata in medicinali di precisione per l'oncologia, ha annunciato la sua partecipazione alla 26ª Conferenza Globale sugli Investimenti Annuale H.C. Wainwright. Il Presidente e CEO dell'azienda, Ron Bentsur, presenterà all'evento il 9 settembre 2024, alle 12:00 PM ET.
Nuvectis si concentra sullo sviluppo di trattamenti innovativi per condizioni gravi con bisogni medici non soddisfatti in oncologia. Questa presentazione a una conferenza d'investimento di rilievo offre un'opportunità all'azienda di mettere in mostra i suoi progressi e il suo potenziale davanti a investitori e professionisti del settore. Le parti interessate possono accedere alla presentazione tramite un link fornito, offrendo un'idea dei progetti attuali di Nuvectis e delle prospettive future nel campo dell'oncologia.
Nuvectis Pharma (NASDAQ: NVCT), una compañía biofarmacéutica en etapa clínica especializada en medicamentos de precisión para oncología, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. El Presidente y CEO de la compañía, Ron Bentsur, presentará en el evento el 9 de septiembre de 2024, a las 12:00 PM ET.
Nuvectis se centra en el desarrollo de tratamientos innovadores para condiciones graves con necesidades médicas no satisfechas en oncología. Esta presentación en una importante conferencia de inversión brinda una oportunidad a la compañía para mostrar su progreso y potencial a inversores y profesionales de la industria. Las partes interesadas pueden acceder a la presentación a través de un enlace proporcionado, ofreciendo una visión de los proyectos actuales de Nuvectis y sus perspectivas futuras en el campo de la oncología.
Nuvectis Pharma (NASDAQ: NVCT)는 암을 위한 정밀 의약품을 전문으로 하는 임상 단계의 생물제약 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Ron Bentsur는 2024년 9월 9일, 오후 12:00 ET에 행사에서 발표할 예정입니다.
Nuvectis는 암 분야에서 충족되지 않은 의료적 필요를 가진 심각한 질병에 대한 혁신적인 치료법 개발에 집중하고 있습니다. 이 중요한 투자 회의에서의 발표는 회사가 투자자와 업계 전문가들에게 자신의 진행 상황과 잠재력을 보여줄 수 있는 기회를 제공합니다. 관심 있는 분들은 제공된 링크를 통해 발표에 접근할 수 있으며, Nuvectis의 현재 프로젝트와 암 분야의 미래 전망에 대한 통찰력을 제공합니다.
Nuvectis Pharma (NASDAQ: NVCT), une société bio-pharmaceutique en phase clinique spécialisée dans les médicaments de précision pour l'oncologie, a annoncé sa participation à la 26ème Conférence Mondiale Annuelle sur les Investissements H.C. Wainwright. Le Président et CEO de l'entreprise, Ron Bentsur, fera une présentation lors de l'événement le 9 septembre 2024, à 12h00 ET.
Nuvectis se concentre sur le développement de traitements innovants pour des conditions graves avec des besoins médicaux non satisfaits en oncologie. Cette présentation lors d'une conférence d'investissement de premier plan offre à l'entreprise l'opportunité de présenter ses progrès et son potentiel aux investisseurs et aux professionnels de l'industrie. Les parties intéressées peuvent accéder à la présentation via un lien fourni, offrant un aperçu des projets actuels de Nuvectis et de ses perspectives futures dans le domaine de l'oncologie.
Nuvectis Pharma (NASDAQ: NVCT), ein Biopharmaunternehmen in der klinischen Phase, das sich auf präzisionsmedizinische Produkte in der Onkologie spezialisiert hat, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Der Vorsitzende und CEO des Unternehmens, Ron Bentsur, wird am 9. September 2024 um 12:00 Uhr ET auf der Veranstaltung präsentieren.
Nuvectis konzentriert sich auf die Entwicklung innovativer Therapien für ernste Erkrankungen mit unerfüllten medizinischen Bedürfnissen in der Onkologie. Diese Präsentation auf einer bedeutenden Investorenkonferenz bietet dem Unternehmen die Möglichkeit, seinen Fortschritt und sein Potenzial Investoren und Fachleuten der Branche vorzustellen. Interessierte Personen können über einen bereitgestellten Link auf die Präsentation zugreifen, die Einblicke in die aktuellen Projekte und zukünftigen Perspektiven von Nuvectis im Bereich der Onkologie bietet.
- None.
- None.
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.
| Event | H.C. Wainwright Global Investment Conference |
| Date | September 9, 2024 |
| Time | 12:00 PM ET |
| Link | https://journey.ct.events/view/5bacb2fb-d0c8-4efa-92b8-7365c030ddd5 |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
rbentsur@nuvectis.com
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com
FAQ
When is Nuvectis Pharma (NVCT) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Nuvectis Pharma (NVCT) at the H.C. Wainwright conference?
What is the focus of Nuvectis Pharma (NVCT)?
How can investors access Nuvectis Pharma's (NVCT) presentation at the H.C. Wainwright conference?
